

February 26, 2020

The Honorable Anna Eshoo
202 Cannon House Office Building
Washington, DC 20515

The Honorable Michael Burgess
2161 Rayburn House Office Building
Washington, DC 20515

Chairwoman Eshoo, Ranking Member Burgess and Members of the Committee:

On behalf of Johnson & Johnson, I am pleased to share information regarding the company's response to the threat of the novel coronavirus (COVID-19) outbreak. Throughout our more than 130-year history, Johnson & Johnson has had a legacy of coming to the aid of local and global communities during times of crisis, from natural disasters to health outbreaks. We believe we have a responsibility to step in and invest in solutions for global public health crises and are proud to be contributing to the global response to COVID-19.


In early January 2020, when the viral sequence became available, Johnson & Johnson began to rapidly mobilize our resources in response to the virus. As part of this work, we have initiated efforts to develop a vaccine candidate against COVID-19, which we hope can ultimately be deployed quickly and extensively to help combat this outbreak. Earlier this month, J&J announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to further expedite our investigational coronavirus vaccine program as well as to accelerate the discovery of potential treatments for the virus. We remain open to collaborating with governments, healthcare professionals and others to ensure rigorous collection of data that will allow evidence generation to guide the use of effective medicines and support the best outcomes for patients affected by the outbreak.

The company has also mobilized quickly to provide crucial donations from across its businesses, as well as other support, to help those impacted. To date, J&J has made available 1 million surgical masks, 50,000 bottles of BAND-AID® Brand Isopropyl Alcohol, and 1 Million Renminbi to the Chinese Red Cross Foundation. Johnson & Johnson Medical Devices Companies China is also providing an electrosurgical generator and other devices to the Red Cross Society of China Wuhan Branch to help supply new isolation hospitals that were constructed quickly to address the growing outbreak.

We believe that global health security is everyone's responsibility and requires coordinated effort from governments, civil society and healthcare companies. We are proud to contribute to global efforts to combat the novel coronavirus through both humanitarian donations and the development of a vaccine and treatment for COVID-19.

Thank you for your attention to this critically important issue. If you have any questions, please e-mail Meghan Stone at mdstone@its.jnj.com or call 202-589-1425.

Sincerely,



Jane M. Adams
Vice President, Federal Affairs